肌少症轨迹预测可手术头颈癌患者的生存
本研究评估可手术的头颈鳞状细胞癌(HNSCC)患者肌少症轨迹与总生存(OS)和无病生存(DFS)的关联。332例II-IV期HPV阴性HNSCC患者中,108例基线存在肌少症,106例治疗后仍存在肌少症。持续肌少症或进展为肌少症的患者OS和DFS显著更差。
要点
- 332例可手术HNSCC患者中,108例基线肌少症,106例治疗后仍肌少症。
- 持续肌少症者OS的HR为2.08(95%CI 1.27-3.41),DFS的HR为1.79(95%CI 1.17-2.72)。
- 进展为肌少症者OS的HR为3.05(95%CI 1.40-6.62),DFS的HR为2.12(95%CI 1.03-4.36)。
核心结论
- 肌少症轨迹可作为预测可手术HNSCC肿瘤学结局的动态生物标志物。
研究设计与样本
- 评估可手术的II-IV期HPV阴性HNSCC患者治疗前后体成分指标,并按肌少症轨迹分组,采用多因素Cox回归分析。
主要发现
- 332例患者中,108例基线存在肌少症,106例治疗后仍存在肌少症。
- 与持续非肌少症者相比,持续肌少症者OS的HR为2.08(95%CI 1.27-3.41),DFS的HR为1.79(95%CI 1.17-2.72)。
- 与持续非肌少症者相比,进展为肌少症者OS的HR为3.05(95%CI 1.40-6.62),DFS的HR为2.12(95%CI 1.03-4.36)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sarcopenia is associated with increased treatment toxicity and survival in head and neck squamous cell cancer (HNSCC). This study evaluates sarcopenia trajectories and their association with overall survival (OS) and disease-free survival (DFS) in operable HNSCC. METHODS: Pre- and post-treatment body composition metrics of patients with stage II-IV HPV-negative HNSCC undergoing surgery were performed. Sarcopenia trajectories were categorized as remains sarcopenic, remains non-sarcopenic, recovers from sarcopenia, or progresses to sarcopenia using multiple Cox regression. RESULTS: Of 332 patients, 108 were sarcopenic at baseline, and 106 remained sarcopenic post-treatment. Patients who remained sarcopenic or progressed to sarcopenia demonstrated significantly worse OS (HR: 2.08, 95% CI: 1.27-3.41 and HR: 3.05, 95% CI: 1.40-6.62) and DFS (HR: 1.79, 95% CI: 1.17-2.72 and HR: 2.12, 95% CI: 1.03-4.36), compared to those who remained non-sarcopenic while adjusting for confounding factors. CONCLUSION: Sarcopenia trajectories represent dynamic biomarkers that predict oncologic outcome in patients with operable HNSCC.
引用
- Mascarella MA, Mlynarek A, Richardson K, et al. Sarcopenia Trajectories Predict Survival in Operable Head and Neck Cancer. Head Neck. 2025. PMID: 40491221. doi:10.1002/hed.28210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。